Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Portfolio Recovery Associates Inc. ( PRAA - Analyst Report ) reported second-quarter 2012 income from continuing operations of $1.87 per share, surpassing the Zacks Consensus Estimate of $1.64. The results also exceeded the prior-year earnings of $1.48.
In the quarter under review, net income came in at $32.0 million, compared with $25.6 million recorded in the second quarter of 2011. Earnings were primarily driven by strong top-line growth attributable to continuous improvement in cash collections.
Portfolio Recovery’s total revenue in the reported quarter was $147.9 million, showing a 29% upside from $114.8 million in the year-ago period. Revenue also surpassed the Zacks Consensus Estimate of $141 million.
The boost in revenue was driven by growth of 30% in cash receipts to $247.7 million from $190.8 million in the prior-year quarter. Portfolio Recovery deployed 42.0% of its cash collections to reduce its owned debt portfolios, up from 41.8% in the year-ago quarter.
Cash collections jumped 32% year over year to $232.4 million from $176.3 million in the year-ago period. Call center and other collections posted a 14% increase, external legal collections gained 52%, internal legal collections surged 58% and purchased bankruptcy collections improved 35%, compared with the prior-year quarter.
However, Portfolio Recovery’s revenue from its fee-for-service businesses was $15.3 million, up from 14.5 million in the year-ago quarter. The increase was mainly due to the revenues from the UK business, which were partially offset by a decline in the fee-for-service revenue from the U.S.
Operating margin declined 280 basis points year over year to 36.9% in the quarter under review. The decline was attributable to higher legal collection expenses.
Balance Sheet and Capital Structure
As of June 30, 2012, cash and cash equivalents increased to $42.6 million from $26.7 million recorded at the end of 2011.
Portfolio Recovery had $292 million outstanding under its line of credit as of June 30, 2012. The remaining borrowing availability under the line was $166.6 million as of June 30, 2012.
Portfolio recovery exited the quarter with total assets of $1.17 billion and shareholders’ equity of $633.4 million.
Share Repurchase Update
Portfolio Recovery has a share repurchase authorization of $100 million. During the second quarter of 2012, the company repurchased 0.30 million shares at an average price of $68.62 under the program. As of June 30, 2012, the company had remaining authorization of $77 million under the share repurchase program.
Our Take
Portfolio Recovery’s bottom-line results have shown great improvement over the past few quarters. Strong cash collections coupled with improved operational efficiency led to an increase in both the top and bottom lines in the reported quarter.
Even the performance of the fee-for-service business showed improvement in the quarter, after posting weak results in the past few quarters. The balance sheet also strengthened with higher cash balance and increased shareholders’ equity.
Portfolio Recovery’s competitor Encore Capital Group Inc. ( ECPG - Snapshot Report ) will report its second-quarter financial results after the market closes on August 2, 2012.
We retain our Neutral recommendation on Portfolio Recovery Associates. The quantitative Zacks #3 Rank (short-term Hold rating) for the company indicates no clear directional pressure on the shares over the near term.
Read the full reports :
Analyst Report on PRAA
Snapshot Report on ECPG